Real-World Trofinetide Treatment Patterns in Rett Syndrome

Trofinetide in Rett syndrome represents a major breakthrough as the first FDA-approved medication for this complex neurodevelopmental disorder. A recent real-world analysis from the United States provides essential data on how patients use this therapy in daily clinical practice. Specifically, researchers examined the treatment habits and persistence of 1,175 individuals who initiated the medication between 2023 and 2024. This evidence is vital for clinicians managing the unique challenges of Rett syndrome.

Long-Term Persistence and Trofinetide in Rett syndrome

The study found that 54.9% of patients remained persistent on the treatment for a median of 14.3 months. Furthermore, more than three-quarters of the initiators continued their therapy beyond the initial three-month mark. However, the data also highlighted that nearly 45% of patients were classified as non-persistent. Interestingly, about 7.6% of those who stopped the medication eventually restarted it. These findings suggest that while many benefit from long-term use, some patients require additional support during the early stages of treatment.

Predictors of Treatment Discontinuation

Identifying why some individuals stop treatment is crucial for improving patient care. Researchers discovered that older age and a history of infectious disorders significantly predicted non-persistence. Moreover, dosing patterns played a surprising role in treatment longevity. Persistent patients typically started at a lower mean twice-daily dose compared to those who discontinued. While persistent users maintained stable dosing over time, non-persistent users experienced much greater dose variability. Therefore, starting with a lower dose and focusing on stability may help more patients remain on therapy.

Clinical Implications for Practice

These real-world results offer practical guidance for neurologists and pediatricians. Because stable dosing correlates with better persistence, clinicians should closely monitor patients during the titration phase. Additionally, addressing comorbidities like infectious disorders might reduce the risk of treatment gaps. Consequently, these insights help healthcare providers set realistic expectations for families and optimize the therapeutic journey for those living with Rett syndrome.

FAQs about Trofinetide Therapy

How long do patients typically stay on trofinetide?

Real-world evidence shows that over half of patients remain on the medication for at least 14 months. Most individuals who successfully navigate the first three months of therapy continue long-term.

What factors increase the risk of stopping treatment?

Older age and a history of infections are primary predictors of non-persistence. Additionally, patients who start at higher doses or experience frequent dose fluctuations are more likely to discontinue.

Does a lower starting dose help with persistence?

Yes, the data suggests that persistent users often begin with a slightly lower average dose than those who stop. Maintaining a stable dosing schedule is also strongly linked to staying on the medication.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Rashid N et al. Rett syndrome and real-world treatment patterns of trofinetide in the United States. J Med Econ. 2026 Dec undefined. doi: 10.1080/13696998.2026.2682668. PMID: 42287113.

Cosand L et al. Real-world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study. Dev Med Child Neurol. 2026 Mar;68(3):407-417. doi: 10.1111/dmcn.16482.

U.S. Food and Drug Administration. FDA approves first treatment for Rett Syndrome. Published March 13, 2023.